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Abstract
Introduction: Tenascin-C (TNC) is a large extracellular matrix glycoprotein that shows prominent stromal
expression in many solid tumours. The profile of isoforms expressed differs between cancers and normal breast,
with the two additional domains AD1 and AD2 considered to be tumour associated. The aim of the present study
was to investigate expression of AD1 and AD2 in normal, benign and malignant breast tissue to determine their
relationship with tumour characteristics and to perform in vitro functional assays to investigate the role of AD1 in
tumour cell invasion and growth.
Methods: Expression of AD1 and AD2 was related to hypoxanthine phosphoribosyltransferase 1 as a housekeeping
gene in breast tissue using quantitative RT-PCR, and the results were related to clinicopathological features of the
tumours. Constructs overexpressing an AD1-containing isoform (TNC-14/AD1/16) were transiently transfected into
breast carcinoma cell lines (MCF-7, T-47 D, ZR-75-1, MDA-MB-231 and GI-101) to assess the effect in vitro on
invasion and growth. Statistical analysis was performed using a nonparametric Mann-Whitney test for comparison
of clinicopathological features with levels of TNC expression and using Jonckheere-Terpstra trend analysis for
association of expression with tumour grade.
Results: Quantitative RT-PCR detected AD1 and AD2 mRNA expression in 34.9% and 23.1% of 134 invasive breast
carcinomas, respectively. AD1 mRNA was localised by in situ hybridisation to tumour epithelial cells, and more
predominantly to myoepithelium around associated normal breast ducts. Although not tumour specific, AD1 and
AD2 expression was significantly more frequent in carcinomas in younger women (age ≤40 years; P < 0.001) and
AD1 expression was also associated with oestrogen receptor-negative and grade 3 tumours (P < 0.05). AD1 was
found to be incorporated into a tumour-specific isoform, not detected in normal tissues. Overexpression of the
TNC-14/AD1/16 isoform significantly enhanced tumour cell invasion (P < 0.01) and growth (P < 0.01) over base
levels.
Conclusions: Together these data suggest a highly significant association between AD-containing TNC isoforms
and breast cancers in younger women (age ≤40 years), which may have important functional significance in vivo.
Introduction
The role of the stromal microenvironment in modulat-
ing breast cancer behaviour is well established [1,2].
A major modulatory component of the stromal environ-
ment is the extracellular matrix, and changes in
extracellular matrix composition may therefore be
expected to be a key factor in determining tumour
behaviour. A consistent feature of the stroma around
many breast carcinomas is upregulation of the extracel-
lular matrix glycoprotein tenascin-C (TNC) [3-5].
TNC is a complex multifunctional protein that can
influence cell behaviour directly and indirectly [6,7]. It
has been shown to promote cell migration [8], to inhibit
focal adhesion formation [9], to induce cell proliferation
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T N Cp r o m o t e sa n g i o g e n e s i s[ 1 1 ]a n dc a ni n d u c e
expression of matrix metalloproteinases [12], which
themselves have been implicated in promoting tumour
growth and invasion [13].
Structurally TNC comprises a linear arrangement of
domains, with a cysteine-rich N-terminus followed by
14.5 epidermal growth factor-like repeats, a region of
fibronectin type III-like repeats and a fibrinogen-like
domain at the C-terminus (Figure 1) [14]. The structure
and size of TNC varies as a result of alternative splicing
of domains within the fibronectin type III repeat
domain; exons 10 to 16 (domains A1 to A4, B, C and
D) can undergo alternative splicing either singly or in
combination. A number of biologically active sites have
been mapped to the fibronectin type III repeat domain,
including recognition sites for cell surface receptors
such as integrins [15], cell adhesion molecules of the
immunoglobulin superfamily [16], and annexin II [17] as
well as sites susceptible to proteolytic cleavage by matrix
metalloproteinases [18]. Inclusion or exclusion of differ-
ent domains in this region can thus generate consider-
able functional diversity, and up to 22 human splice
variants have been identified by RT-PCR analysis [19].
Changes in the profile of TNC isoforms expressed in
tumours compared with normal tissue have been
described. A switch from the small or truncated form of
TNC, which lacks exons 10 to 16, to predominant
expression of the large, full-length variant of TNC has
been demonstrated in breast, lung and colorectal carci-
noma [20-22]. In glioblastoma, upregulation of an
isoform containing exon 15 (domain C), which is rarely
detected in normal tissues or malignant epithelium, has
been demonstrated [23]. We previously identified induc-
tion of two intermediate-sized TNC isoforms in breast
cancers [24] and showed that these isoforms can
enhance tumour cell invasion [25]; a similar change was
demonstrated in ovarian carcinomas [26]. Although the
precise significance of alter e dT N Ci s o f o r me x p r e s s i o n
is not well understood, it seems likely that different iso-
forms have distinct biological function, a concept sup-
ported in recent studies [25,27].
Two less-studied repeat regions have been identified
in human, mouse and avian TNC, termed additional
domain (AD) 1 and AD2, inserted between domains B
and C [28-30]. Transcripts encoding AD1 have been
detected in a variety of cancers [31], whilst inclusion
of AD2 has so far been described only in oral squa-
mous carcinomas [28]. Expression of both repeats has
been detected in embryonic avian tissue. Interestingly,
in situ hybridisation demonstrated that TNC-AD1
mRNA is abundant at sites of cell motility and branch-
ing morphogenesis, suggesting that inclusion of this
repeat may contribute to the migration-promoting
effect of TNC [31].
The potential to exploit tumour-specific, alternatively
spliced isoforms as therapeutic targets has already been
demonstrated [32]. The aims of the present study were
therefore to establish whether TNC-AD1 and/or TNC-
AD2 domains represent tumour-associated isoforms in
breast cancer, to determine whether expression of these
isoforms correlates with clinicopathological features and
Figure 1 Schematic representation of tenascin-C. Protein structure illustrating the N-terminal tenascin assembly domain, the epidermal
growth factor (EGF)-like repeat region, the fibronectin type III-like region and the C-terminal fibrinogen-like domain. Exon organisation is shown
below (adapted from [25]). Note that the first exon of TNC is not translated and is shown in grey; therefore, exon number 1 in this figure is the
first coding exon. UTR, untranslated region.
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profiling [33,34], and to use in vitro studies to investi-
gate the functional significance of a TNC isoform con-
taining the AD1 domain to tumour cell behaviour. The
results of the study show that TNC-AD domains are
significantly associated with breast cancers in younger
women (age <40 years), with high grade and with oes-
trogen receptor (ER)-negative status. Moreover, in vitro
cell culture models show that, in some cell backgrounds,
AD1-containing isoforms promote tumour cell invasion
and growth at a higher level than that seen with vector
controls and other TNC isoforms.
Materials and methods
Tissues and cells
Fresh and/or formalin-fixed tissue was obtained from
patients undergoing breast surgery in accordance with
Ethics Approval from Leicestershire Research Ethics
Committee (06/Q2502/70) and North East London
Research Ethics Committee (05/Q0403/199). Since all
samples were anonymised there was no requirement
from either research ethics committee for informed con-
sent. For isolation of normal cells, tissue was obtained
from women undergoing breast reduction surgery who
gave informed consent (LNRREC 7054).
Two hundred and four samples were analysed from
155 carcinomas selected based on age (68 infiltrating
ductal carcinomas from women aged ≤40 years, 62 infil-
trating ductal carcinomas from women aged >40 years,
25 infiltrating lobular carcinomas from women aged >40
years), two cases of ductal carcinoma in situ,1 4b e n i g n
breast lesions including fibroadenoma and fibrocystic
change, and 33 normal breast samples from reduction
mammoplasty procedures. Tissue was either snap-frozen
in liquid nitrogen or routinely processed and paraffin-
embedded following formalin fixation. In selected nor-
mal samples, tissue was processed and enzymatically
digested to yield single-cell populations, and myoepithe-
lial cells, luminal epithelial cells and fibroblast cells were
isolated and characterised as described previously [35].
Breast cell lines (MCF-7, ZR-75-1, T47 D, Hs578T,
MDA-MB-231, MDA-MB-468, MDA-MB-436, HBL-100
and MCF-10A) were obtained from American Type Cul-
ture Collection (Rockville, MD, USA). Most cell lines
were maintained in DMEM plus 2 mM L-glutamine and
10% FBS. ZR-75-1 and MDA-MB-436 cell lines were
maintained in RPMI supplemented with 10% FBS. The
MCF-10A cell line was maintained in a 1:1 mixture of
Ham’s F12 (Invitrogen Life Science, Carlsbad, CA, USA)
and DMEM, 2 mM glutamine supplemented with 5%
heat-inactivated horse serum, insulin (10 μg/ml), hydro-
cortisone (0.5 μg/ml) and epidermal growth factor (20
ng/ml) (all SigmaGenosys, Dorset, UK).
Transfection of breast carcinoma cell lines
Breast cancer cell lines MCF-7, T-47 D, ZR-75-1, MDA-
MB-231 and GI-101 were transiently transfected with a
novel TNC-14/AD1/16 construct, generated by PCR
ligation using previously generated plasmids (TNC-S,
TNC-L, TNC-9/14/16) [25] and a Vector control (empty
pCMV Script vector) and FuGene HD transfection
reagent (Roche, Welwyn Garden City, UK) according to
the manufacturer’s protocol. For endogenously TNC-
expressing cell lines, co-transfection with the pmaxGFP
vector (Lonza, Slough, UK) was also performed to assess
transfection efficiency. TNC expression was confirmed
using immunohistochemistry for TNC-null cell lines.
For all cell lines, expression was also confirmed by
quantitative RT-PCR. Transfection efficiencies for each
isoform were confirmed by estimating the proportion of
cells that were either immunostained positive or were
expressing green fluorescent protein (GFP).
RNA isolation and generation of cDNA
RNA was isolated from frozen tissue for 64 tumour
samples, all benign and normal samples and 1 × 10
5
cells from each breast cell line using Tri-reagent
(Sigma). Seventy tumour tissue samples were available
from a previous study in which mRNA was isolated
using oligo-dT-linked Dynabeads® (Dynal, Bromborough,
UK). Total RNA (1 μg) or all bead-isolated mRNA was
reverse transcribed at 42°C for 1 hour using Expand-RT
(Boehringer Mannheim, Welwyn Garden City, UK) as
described previously [24].
Quantitative polymerase chain reaction
Owing to limiting amounts of tissue, a nested quantita-
tive PCR approach was devised to amplify TNC exons
from frozen tissues. First-round PCR comprised 20
cycles of amplification with primers located in domain 4
(exon 8) and domain 7 (exon 18), to amplify the entire
alternative spliced region of TNC (TNC 8/18). Taqman
real-time PCR (Applied Biosystems, Foster, CA, USA)
was then applied to survey different exons. Inventoried
assays were available for the Tenascin-C invariant exon
17/18 boundary (Applied Biosystems Taqman Assay,
Hs01115654_m1) and hypoxanthine phosphoribosyl-
transferase 1 (Applied Biosystems Taqman Assay,
Hs99999909_m1) as a housekeeping gene. Primers and
probes were developed in-house for AD1 and AD2
(Table 1). For the inventoried Taqman assays, 4 μl
cDNA (diluted 1:10) was analysed in a reaction contain-
ing 0.5 μl probe, 0.5 μlu l t r a - p u r eH 2Oa n d5μlo f2×
Taqman Fast PCR mastermix. For the AD1 and AD2
assays, 3.6 μl cDNA (diluted 1:10) was analysed in a
reaction containing 0.2 μl probe, 0.6 μl each primer and
5 μl of 2 × Taqman Fast PCR mastermix.
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(11 carcinomas in women aged ≤40 years and 11 carci-
nomas in women aged >40 years), AD1, AD2 and exon
17/18 were also assayed directly to enable evaluation of
AD1 and AD2 expression relative to total TNC expres-
sion (exon 17/18). All quantitative PCR analysis was
performed using Step-One qPCR software (Applied Bio-
systems). The number of cycles necessary to produce a
product above background (Ct value) was recorded and,
after normalisation to the Ct value for hypoxanthine
phosphoribosyltransferase 1, the relative expression was
determined with the following formula:
Relative expression Ct = − 2 ( ) ΔΔ
Determination of TNC transcript expression
The number of TNC transcripts was calculated using a
standard curve generated from nested isoform-specific
8/18 PCR products. This was then used to calculate the
number of molecules in a known concentration of sam-
ple. A log2 value was then produced from the mean Ct
value and normalised against the mean Ct values for the
endogenous controls.
Sequencing
AD1 amplicons were analysed by DNA sequencing. Pro-
ducts were sequenced from AD1-F and AD1-R primers,
respectively (Table 1), using 1 μlB i gD y eT e r m i n a t o r
reactions (ABI, Beverley, UK) and analysed on an ABI
Prism 377 DNA sequencer. Sequence profiles were ana-
lysed using the Chromas software (version 2.3; Techne-
lysium Pty, Ltd Eden Prairie, MN, USA).
Immunohistochemistry
Immunohistochemistry for cytokeratin (CK) 14 (Sigma),
CK5/6 (Sigma) and P-cadherin (BD Biosciences Cowley,
UK) was performed on 4 μm formalin-fixed, paraffin-
embedded (FFPE) serial sections from a subset of 96
breast carcinomas. A standard avidin-biotin complex
technique was employed with citrate buffer microwave
antigen retrieval for P-cadherin. Normal breast tissue
was used as a positive control for all antibodies. Nega-
tive controls involved omission of the primary antibody.
Sections were scored positive for CK14, CK5/6 or P-
cadherin if >10% of the tumour cells were stained. The
ER and progesterone receptor were examined in 138
tumour cases, and HER2 examined in 134 cases [36].
All interpretation was carried out by RAW and JLJ.
Western blotting
Levels of cellular and secreted TNC isoforms were deter-
mined by western blotting of transfected cell lysates and
serum-free culture media respectively. Cells were transi-
ently transfected and incubated for 24 hours, serum-free
media was added and the culture media was collected a
further 48 hours after transfection. Protein concentra-
tions were quantified on a Lambda 25 UV/VIS spectro-
photometer at 750 nm using the bovine serum albumin
protein assay, and equal amounts of protein were loaded
onto 6% SDS-PAGE gels and transferred to Hybond ECL
nitrocellulose membrane (Amersham Biosciences, Little
Chalfont, UK). Membranes were blocked in Tris-buffered
saline, 5% milk and 1% Tween for 1 hour and were
probed for 1 hour with a rabbit polyclonal TNC antibody
(clone H300, recognising all forms of TNC; Santa-Cruz
Biotechnology, Santa Cruz, CA, USA). A secondary anti-
body, donkey anti-rabbit horseradish peroxidase-linked
IgG (1:2,000; Amersham Biosciences), was added for 1
hour and blots were detected using an enhanced chemi-
luminescence detection kit (Amersham Biosciences).
In situ localisation of AD1-containing mRNA
Single-stranded sense and antisense AD1 and b-actin
control DNA probes were synthesised using asymmetric
PCR [24] with specific primers (Table 1) and incorpora-
tion of digoxigenin-11-dUTP. In situ hybridisation was
carried out on 4 μm de-waxed rehydrated tissue sections
as described previously [24]. The optimum probe con-
centration (200 to 500 ng/ml) was titrated to eliminate
background staining, whilst retaining good signal
strength. Negative controls used sense probes, RNase
pretreatment of tissue sections and omission of the
probe in the hybridisation protocol.
Analysis of tumour cell invasion
Measurement of tumour cell invasion was based on
modified Boyden Chamber assays using the Fluoroblok
Table 1 Primer sequences for RT-PCR and asymmetric
PCR
Primer Sequence 5’ to 3’
T8 - forward CAATCCAGCGACCATCAACG
T18 - reverse CGTCCACAGTTACCATGGAG
T16 - reverse GTTGTCAACTTCCGGTTCGG
AD1 - forward TGGTGGAGAACACTGGCTATGAC
AD1 - reverse GGGATCCCCAGCCAAGGT
AD1-FAM-MGB CAGTGTGGCAGGAAC
AD2 - forward GATCACCCCCATGAGACCAT
AD2 - reverse TGATGACAGAGCTGC GAGACA
AD2-FAM-MGB TGCTGTCTGTGCCTGG
GAPDH - forward AGAACATCATCCCTGCCTC





Sense and antisense primers were used to generate single-stranded DNA
probes for in situ hybridisation.
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To measure the direct effect of TNC isoform expression
on tumour cell invasion, transiently transfected cells
were placed in the upper chamber of the assay and
DMEM containing 10% (v/v) FCS was added to the
lower chamber as a chemotactic stimulus - except for
the MDA-MB-231 cell line, where DMEM containing
1% (v/v) FCS was used. Assays were monitored in real
time up to 48 hours with readings every 2 hours and for
a total of six replicates representing three separate trans-
fections. Relative fluorescence to time 0 was used as a
measure of invasion for each time point,
Analysis of tumour cell growth
The direct effects of TNC isoform expression on
tumour cell growth were assessed using 4’,6-diamidino-
2-phenylindole staining of cell nuclei as described pre-
viously [38]. Tumour cells were transfected, and cul-
tured for 48 hours in DMEM containing 10% (v/v) FCS.
Cells were washed with PBS, fixed in cold acetone/
methanol (1:1) for 2 minutes and washed twice with
PBS. Cells were then stained using 4’,6-diamidino-2-phe-
nylindole (1:20,000) in PBS for 3 minutes and washed
twice with PBS. Cell nuclei were examined using a fluor-
escence microscope and counted using an in-house soft-
ware program provided by Dr AE Sayan (University of
Leicester, UK) [38]. Each experiment was performed for
a total of nine replicates representing three separate
transfections.
Statistical analysis
Statistical analysis was performed using SPSS 16 (SPSS
Inc, Chicago, Illinois, USA). Relationships between factors
were measured using the nonparametric Mann-Whitney
test, except for grade where Jonckheere-Terpstra trend
analysis was applied. All tests were two-sided and P < 0.05
was considered significant. For functional assays, two-way
analysis of variance was performed.
Results
Expression of TNC-AD1 and TNC-AD2 in breast cell lines
and isolated cell populations
Nine breast cell lines and isolated normal breast myoe-
pithelial cells and fibroblast cells were screened for
expression of TNC 17/18 (an invariant exon boundary,
present in all TNC splice variants), AD1 and AD2 by
real-time quantitative PCR. TNC 17/18, AD1 and AD2
were absent from ER-positive MCF-7, ZR-75-1, and T-
47 D cells (Table 2). Of the AD1-positive cell lines,
MDA-MB-436, HBL-100 and primary normal myoe-
pithelial cells expressed the highest levels (>400,000
molecules per 1 μg RNA). All AD1-positive cell lines
and isolated breast cell populations also expressed AD2,
but at lower levels. When AD1 and AD2 expression was
related to levels of total TNC expression, HS578T,
HBL100 and primary myoepithelial cells showed the
highest percentages of AD1 (>25% total TNC) and
HS578T and MCF10A cells showed the highest AD2
percentages (>5% total TNC).
Expression of TNC-AD1 and TNC-AD2 in breast tissues
RNA was successfully isolated from 134 carcinomas, all
14 benign breast tissue samples and 33 normal breast
tissue samples, demonstrated by detection of GAPDH
by manual PCR. All samples were then analysed by
quantitative RT-PCR for expression of the invariant
TNC exon 17/18 boundary (total TNC), AD1 and AD2.
Total TNC was detected in all samples apart from two
of the carcinomas. AD1 expression was demonstrated
in 42 (31%) carcinomas, five benign breast tissues and
Table 2 Relative expression of tenascin-C, AD1 and AD2 in cell lines and isolated normal breast cells
Number of TNC transcripts (×10
3) % of total TNC transcripts
Cell line Total TNC AD1 AD2 AD1 AD2
ZR-75-1 0 0 0 0 0
T-47D 0 0 0 0 0
MCF-7 0 0 0 0 0
Hs578T 162.651 41.432 14.574 25.47 8.96
MDA-MB-231 1,293.947 44.383 23.821 3.43 1.84
MDA-MB-436 8,409.526 479.824 55.735 5.71 0.66
MDA-MB-468 984.727 89.74 28.784 9.11 2.92
GI-101 1,529.834 143.854 8.433 9.40 0.55
HBL-100 15,017.045 6,671.261 483.212 44.42 3.22
MCF-10A 91.37 7.399 6.933 8.10 7.59
Primary MEC 2,925.394 1,863.143 142.39 63.69 4.87
Primary fibroblasts 5398.821 87.867 98.044 1.63 1.82
Percentage expression of additional domain (AD) 1 and AD2 relative to the invariant exon 17/18 boundary, as a marker of total tenascin-C (TNC) expression,
normalised to the hypoxanthine phosphoribosyltransferase 1 control in cell lines and isolated normal breast cells. MEC, myoepithelial cells.
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women aged <40 years). TNC-AD2 was less frequent
than TNC-AD1, being detected in 31 (23.1%) carcino-
mas, four benign breast tissue samples and four normal
breast samples. Nineteen carcinomas, one benign sample
and one normal sample expressed both AD1 and AD2.
TNC-AD1 and TNC-AD2 expression in relation to
clinicopathological features of carcinomas
When quantitative data were compared with clinico-
pathological features of the carcinomas, expression of
AD1 was significantly associated with grade 3 tumours,
ER-negative status and with younger patient age (≤40
years) (Table 3). AD2 expression was also significantly
associated with younger patient age (Table 3). When the
data were stratified by presence of exons only, 19 carci-
nomas were positive for both AD1 and AD2 - 16 of
these were from women aged ≤40 years (P <0 . 0 0 1 ;F i g -
ure 2), and the highest frequency of TNC-AD1-positive
and TNC-AD2-positive tumours was seen in women
aged between 31 and 35 years. Neither AD1 nor AD2
showed any association with lymph node status.
For 22 of the carcinomas (11 carcinomas in women
aged ≤40 years, 11 carcinomas in women aged >40
Table 3 Relationship between expression of total TNC, TNC-AD1 and TNC-AD2 and clinicopathological features of
tumours
Clinicopathological feature Total TNC TNC-AD1 TNC-AD2
n Mean Ct (95% CI) P Mean Ct (95% CI) P Mean Ct (95% CI) P
Age
≤40 years 47 23.5 (21.8 to 25.3) 0.006 36.6 (35.4 to 37.7) <0.001 37.7 (36.7 to 38.6) 0.001
>40 years 87 26.5 (25.7 to 27.3) 38.7 (38.1 to 39.3) 39.1 (38.5 to 39.7)
Tumour type
IDC 109 25.4 (24.4 to 26.4) 0.554 37.8 (37.2 to 38.4) 0.079 38.7 (38.2 to 39.2) 0.760
ILC 25 25.6 (24.7 to 26.5) 38.6 (37.1 to 40.0) 38.3 (36.5 to 39.9)
Grade
I 14 27.6 (25.9 to 29.4) 0.109 39.1 (37.9 to 40.3) 0.017 39.8 (39.3 to 40.2) 0.066
II 63 25.7 (24.6 to 26.7) 38.3 (37.4 to 39.1) 38.7 (37.9 to 39.5)
III 57 24.7 (23.2 to 26.1) 37.3 (36.4 to 38.2) 38.2 (37.4 to 39.0)
Lymph node
Positive 63 25.4 (24.2 to 26.6) 0.802 37.9 (37.2 to 38.8) 0.978 38.8 (38.2 to 39.4) 0.900
Negative 68 25.5 (24.4 to 26.7) 37.9 (37.1 to 38.8) 38.5 (37.7 to 39.3)
Not known 3
Oestrogen receptor
Positive 89 25.6 (24.6 to 26.5) 0.413 38.2 (37.6 to 38.9) 0.011 38.7 (38.1 to 39.3) 0.316
Negative 31 24.1 (22.2 to 26.1) 36.7 (35.3 to 38.0) 38.1 (36.9 to 39.3)
Not known 14
Progesterone receptor
Positive 79 25.4 (24.5 to 26.4) 0.431 37.9 (37.2 to 38.4) 0.441 38.8 (38.2 to 39.3) 0.641
Negative 36 24.5 (22.6 to 26.4) 37.6 (36.4 to 38.7) 38.1 (36.8 to 39.5)
Not known 19
Her-2
Positive 17 23.3 (20.5 to 26.2) 0.232 37.6 (35.9 to 39.3) 0.639 38.2 (36.6 to 39.8) 0.452
Negative 81 25.1 (24.2 to 26.1) 37.8 (37.0 to 38.6) 38.7 (38.0 to 39.4)
Not known 36
Basal 1
Positive 23 24.3 (22.2 to 26.4) 0.605 36.9 (35.3 to 38.6) 0.170 38.4 (37.2 to 39.7) 0.746
Negative 109 25.4 (24.5 to 26.3) 38.0 (37.4 to 38.7) 38.6 (37.9 to 39.1)
Not known 2
Basal 2
Positive 22 25.8 (23.1 to 28.4) 0.103 37.6 (35.9 to 39.4) 0.960 38.5 (37.3 to 39.6) 1.000
Negative 51 23.2 (21.4 to 25.0) 37.6 (36.6 to 38.7) 38.5 (37.7 to 39.3)
Not known 61
CI, confidence interval; Ct, number of cycles necessary to produce a product above background; IDC: infiltrating ductal carcinoma; ILC: infiltrating lobular
carcinoma; TNC, tenascin-C.
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The total number of TNC molecules and transcripts
containing AD1 was greater in carcinomas from younger
women (Table 4). It was not possible to statistically ana-
lyse AD2 expression since only four samples were
positive.
TNC-AD1 and TNC-AD2 expression was also ana-
lysed in relation to the tumour subtype, as determined
by immunohistochemical profiling [33,34]. Nielsen and
colleagues considered that lack of ER and HER2 and
presence of epidermal growth factor receptor (HER1)
and CK5/6 could identify basal-like carcinomas [34].
Carey and colleagues defined basal-like carcinomas as
ER-negative, PR-negative, Her2-negative, CK5/6-positive
and/or CK14-positive [33]. There has been debate as to
whether triple-negative cancers (that is, ER-negative,
PR-negative, HER2-negative) are the same as basal-like
tumours [39]. Rakha and colleagues have recently pro-
posed that CK5/6 and/or CK14 can be used to define
basal-like carcinomas irrespective of the expression of
t h eo t h e rm a r k e r s[ 4 0 ] .W et h e r e f o r ec h o s et oe x a m i n e
a range of putative basal markers (ER, PR, HER2, CK5/
6, CK14, and P-cadherin [41]) and compared the expres-
sion of these with AD1and AD2 expression.
Figure 2 Distribution of additional domain-positive and
additional domain-negative breast carcinomas in relation to
patient age. Number of carcinomas positive or negative for both
additional domain AD (1) and AD2. Box contains cases within the
lower and upper quartiles, and the line indicates median age. The
whiskers connect the youngest and oldest patients that are not
outliers; o, outliers; *, extreme values, defined as more than three
box-lengths from the box. TNC, tenascin-C.
Table 4 Tenascin-C transcript levels in carcinomas stratified by age
Number of molecules Mean
Age Sample Total TNC TNC-AD1 TNC-AD2 Total TNC TNC-AD1 TNC-AD2
≤40 years T1 1,212,265 52,620 0 143,696,985 8,944,007 2,027,925
T2 99,024,132 1,567,084 0 (P=0.005) (P=0.030)
T3 2,088,668 150,030 118,774
T4 958,188 58,137 0
T5 4,701,400 0 0
T6 14,962,216 0 0
T7 11,837,854 197,415 0
T8 339,673 0 0
T9 192,103,000 17,251,715 11,618,505
T10 1,100,396,396 79,107,073 10,569,893
T11 153,043,046 0 0
>40 years T12 37,859,646 0 0 4,677,309 25,914 2,211
T13 208,821 37,702 24,325
T14 7,992,309 0 0
T15 66,360 7,451 0
T16 897,614 0 0
T17 73,244 0 0
T18 1,206,237 229,110 0
T19 168,882 9,045 0
T20 276,036 0 0
T21 6,970 1,746 0
T22 2,694,279 0 0
Normalised expression of tenascin-C (TNC) molecules in carcinomas from women aged ≤40 years and >40 years. Mann-Whitney tests were used to calculate P
values.
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Page 7 of 14Immunohistochemical profiling and TNC-AD1/AD2
status was known in 132 cases (59 women aged ≤40
years and 73 women aged >40 years) for basal pheno-
type 1 defined as triple-negative tumours, and in 73
cases (44 women aged ≤40 years and 29 women aged
>40 years) for basal phenotype 2 defined as CK5/6-posi-
tive and/or CK14-positive tumours. There was no signif-
icant relationship between TNC-AD1/AD2 status and
either basal phenotype (Table 3). There was also no
relationship between TNC-AD1/AD2 status and either
HER-2 or P-cadherin expression (data not shown).
The AD1 domain is part of novel intermediate-sized TNC
isoforms
Sequencing was carried out on two tumour samples that
showed expression of two different-sized AD1-contain-
ing isoforms (Figure 3a), the largest of which was
tumour specific. Blast sequence analysis confirmed that
AD1 was located within one of two different intermedi-
ate-sized TNC transcripts between exons 9/14 and
either exons 15/16 or exon 16 alone (Figure 3b;
sequence of AD1 [GenBank:EU295718]) [42]. Neither
isoform contained AD2. Analysis of normal breast cell
populations isolated from reduction mammoplasties
demonstrated a single-isoform TNC-14/AD1/16 in
myoepithelial cell populations from five separate donors
and in five out of 12 fibroblast populations.
TNC-AD1 is derived largely from epithelial cells
In situ hybridisation was carried out on eight breast car-
cinomas with known TNC-AD1 status using TNC-AD1
probes and b-actin as a control (Figure 4). Specificity of
signal was established using sense probes, which were
consistently negative. Two carcinomas, which were
negative for TNC-AD1 by quantitative RT-PCR, were
also negative by in situ hybridisation. In six TNC-AD1-
positive breast carcinomas, the TNC-AD1 antisense
probe localised to tumour cells and not to stromal cells
(Figure 4a); and in the associated myoepithelial cells
around large histologically normal ducts, there was a
lower level of expression detected (Figure 4b).
Direct effects of TNC isoforms on invasion and growth
Although the exon 15-containing isoform (TNC-14/
AD1/15/16) was successfully cloned, it was not
expressed at the protein level (as determined by western
blotting - see Additional file 1) and therefore functional
studies focused on the TNC-14/AD1/16 isoform. Tran-
sient transfection was used to determine the direct
effects of TNC isoforms (TNC-S, TNC-9/14/16, TNC-
14/AD1/16) on invasion in the three TNC null cell lines
(MCF-7, T-47 D, ZR-75-1) and in two cell lines with
endogenous TNC expression (MDA-MB-231 and GI-
101) (Figure 5). All cell lines transfected with TNC-S
showed no significant increase in invasion compared
with vector controls. TNC-14/AD1/16-transfected MCF-
7, T-47 D, MDA-MB-231 and GI-101 cells showed
increased invasion over vector controls, which became
significant with increasing time (Table 5). No significant
increase in invasion was evident in the ZR-75-1 cell line.
TNC-9/14/16-transfected MCF-7 and GI-101 cells also
showed increased invasion over vector controls with
time. No significant increase in invasion was observed in
T-47 D, ZR-75-1 or MDA-MB-231 cell lines (Figure 5
and Table 5). A similar trend in invasion was observed
when compared with TNC-S; however, significance
appeared at a later time point (Table 5). In MCF-7 cells
we also compared mean invasion induced by TNC-14/
AD1/16 and TNC-L (this isoform contains all of the
exons in the alternatively spliced region, with the excep-
tion of AD1 and AD2). TNC-14/AD1/16 significantly
enhanced tumour cell invasion over cells expressing
TNC-L (P < 0.001) (Figure 5a:v). Quantitative RT-PCR
analysis of transfected TNC expression showed
Figure 3 Identification of two distinct additional domain-1-containing tenascin-C isoforms. (a) RT-PCR analysis in two breast cancers using
T8-F and AD1-R primers (Tracks 1 and 2) and using AD1-F and T16-R primers (Tracks 3 and 4). B, blank lane; L, ladder. (b) Two alternatively
spliced isoforms identified by sequencing, shown schematically.
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Page 8 of 14Figure 4 In situ localisation of tenascin-C additional domain 1 to tumour cells and normal myoepithelial cells. (a) An example of
infiltrating ductal carcinoma positive for tenascin-C additional domain 1 (TNC-AD1) by RT-PCR: (i) H & E; (ii) in situ hybridisation using antisense
probe to the TNC-AD1 domain, demonstrating signal in tumour cells; (iii) ISH using TNC-AD1 sense probe as a negative control. (b) A normal
breast duct with adjacent tumour cells within a lymphovascular space: (i) H & E; (ii) ISH with antisense probe to TNC-AD1 showing signal in
scattered myoepithelial cells of normal ducts as well as localised to tumour cells; (iii) ISH with TNC-AD1 sense probe as a negative control.
Figure 5 Direct effects of tenascin-C isoform expression on tumour cell invasion. (a) Monitoring tumour cell invasion in real time using a
modified Boyden chamber assay in (i) MCF-7, (ii) T-47 D, (iii) MDA-MB-231 and (iv) GI-101 cell lines transfected with three different TNC isoform
constructs and the vector control; and (v) invasion of MCF-7 cells transfected with TNC-L and TNC-14/AD1/16 constructs. In all cases, data points
represent the mean of six replicates representing three separate transfections; error bars shown. (b) Quantitative RT-PCR of total TNC transcripts
(exons 17/18) from cells transfected with TNC constructs.
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Page 9 of 14equivalent levels between constructs in all cell lines -
except in MCF-7 cells, which showed TNC-S to be
expressed at a higher level (Figure 5b).
Transient transfection was also used to determine the
direct effects of TNC isoforms (TNC-S, TNC-9/14/16,
TNC-14/AD1/16) on cell growth in MCF-7, T-47 D and
MDA-MB-231 cells. A significant increase in cell num-
ber was observed 48 hours post transfection in both
MCF-7 and MDA-MB-231 cells overexpressing TNC-9/
14/16 and TNC-14/AD1/16 (P <0 . 0 1a n dP < 0.001,
respectively, for MCF-7 cells; P < 0.001 for both iso-
forms in MDA-MB-231 cells) compared with the vector
control. Furthermore, a significant increase was
observed in MCF-7 cells overexpressing TNC-S (P <
0.01). No significant increase was observed in MDA-
MB-231 cells overexpressing TNC-S. MDA-MB-231
cells overexpressing TNC-9/14/16 and TNC-14/AD1/16,
however, showed a significant increase in cell numbers
compared with TNC-S (P < 0.001 for both). No signifi-
cant differences were found between isoforms and
vector controls for T-47 D cells (Figure 6).
Discussion
The TNC isoforms containing AD1 and/or AD2 have
been suggested to be tumour specific [28,31], and TNC-
AD1 may contribute to a motility-promoting environ-
ment [30]. The present study has shown that expression
of only one AD1-containing variant (TNC-14/AD1/15/
16) was cancer specific, but higher mRNA levels of all
AD1 and AD2 variants were associated with high-grade,
ER-negative breast cancers, and cancers arising in
younger women. Detection of AD2-containing isoforms
was less frequent and at lower levels; we therefore
focused on determining the functional significance of
AD1 variants and showed that the TNC-14/AD1/16
isoform promoted invasion and growth.
The present study analysed a series of breast cancer
cell lines and also isolated cell populations from normal
breast (n > 5). Quantitative RT-PCR demonstrated
expression of TNC-AD1 and TNC-AD2 isoforms in all
TNC-positive lines, which were also ER-negative and
were characterised by aggressive behaviour [43-45]. Ana-
lysis of isolated cell populations from normal breast
showed that the predominant source of AD1 and AD2
expression is the myoepithelium. Isolated stromal fibro-
blasts, the source of most TNC isoforms [24], showed
only low-level expression that was not detected for AD1
by in situ hybridisation. The HBL-100 cell line also
showed a high level of expression, and this exhibits
myoepithelial cell characteristics [46]. AD1 was not
detectable in normal tissues by in situ hybridisation; but
was detected at a low level in isolated enriched popula-
tions of a single normal cell type. For the breast cancers,
the cells expressing AD1 were predominantly malignant
epithelial cells rather than fibroblasts. Sequencing of the
two AD1 variants identified in cancers, with AD1 incor-
porated into an isoform containing exons 15 plus 16 or
exon 16 alone, are distinct from those described by
Mighell and colleagues [28]. In their study of oral tis-
sues, AD1-containing isoforms were identified in normal
and reactive lesions as well as tumour tissue, with TNC-
AD2 expression rare but tumour specific. In the present
study, the TNC-14/AD1/15/16 variant was cancer speci-
fic as this was not detected in any of the normal tissues
or isolated cell populations.
We demonstrated that the TNC-14/AD1/16 isoform
significantly increased breast cancer cell invasion and
growth. The largest TNC isoform (TNC-L) has been fre-
quently associated with an invasive phenotype [6,9,27],
as have two other prominent isoforms containing exons
16 and 14/16 [24,25]. The TNC-14/AD1/16 isoform
showed a much greater effect on tumour cell invasion
Table 5 Analysis of cell invasion following transient transfection with tenascin-C isoforms
Cell line
Isoform Time (hours) MCF-7 T-47D MDA-MB-231 GI-101 ZR-75-1
TNC-S 12 NS NS NS NS NS
24 NS NS NS NS NS
36 NS NS NS NS NS
48 NS NS NS NS NS
TNC-9/14/16 12 NS NS NS NS NS
24 NS NS NS NS NS
36 P <0.05 (NS) NS (NS) NS (NS) P < 0.05 (<0.05) NS (NS)
48 P < 0.001 (<0.05) NS (NS) NS (NS) P < 0.001 (0.05) NS (NS)
TNC-14/AD1/16 12 NS NS NS NS NS
24 P < 0.05 (NS) P < 0.05 (NS) P < 0.01 (NS) NS (NS) NS (NS)
36 P < 0.001 (<0.001) P < 0.001 (<0.001) P < 0.001 (<0.01) NS (NS) NS (NS)
48 P < 0.001 (<0.001) P < 0.001 (<0.001) P < 0.001 (<0.001) P < 0.01 (NS) NS (NS)
Significance at 12-hour intervals relative to vector-only controls (relative to TNC-S). NS, not significant.
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Page 10 of 14than TNC-L in MCF-7 cells, however, suggesting that
these intermediate-sized isoforms may be most biologi-
cally relevant. TNC-14/AD1/16 also produced a greater
effect than the TNC-9/14/16 isoform, but this was only
significant for MCF-7 and T-47 D cells. The fully trun-
cated TNC isoform (TNC-S) showed no significant
effect on tumour cell invasion, consistent with previous
reports [25].
The TNC-14/AD1/16 isoform was also shown to
increase cell growth in MCF-7 cells at a similar level to
isoform TNC-9/14/16, supporting our previous data
[26]. In cells that endogenously express TNC (that is,
MDA-MB-231), however, transfection with TNC-14/
AD1/16 had a much greater effect on cell growth. The
precise mechanisms leading to increased cell invasion
and growth in the breast are unclear. Ruiz and collea-
gues [47] and Lange and colleagues [48] have associated
triggering of glioma cell migration with a simultaneous
mechanism of competitive inhibition of syndecan-4
binding of fibronectin and signalling by lysophosphatidic
acid and platelet-derived growth factor (reviewed in
[49]). Furthermore, TNC has been shown to be suscepti-
ble to degradation by matrix metalloproteinases [50,51],
which can reveal cryptic sites present in the TNC mole-
cule [52] - of which AD1 could be a potential site.
Further work using peptide fragments containing AD1
could help elucidate these functions.
High expression of either AD1-containing or AD2-
containing mRNA in breast cancers was significantly
associated with young patient age (≤40 years). AD1
expression was also associated with lack of ER and
grade 3 tumours, both of which are features of cancers
in younger women. These results correlate with findings
by Helleman and colleagues, who suggested that high
TNC expression could be an indirect marker for a
defective ER pathway due to an inverse correlation
between TNC mRNA and ER protein expression [53].
Breast carcinomas in young women exhibit a particu-
larly aggressive phenotype compared with tumours aris-
ing in postmenopausal women [54-56]. This may in part
be attributed to the greater frequency of high-grade
tumours in young women [57]. There is evidence that
Figure 6 Direct effect of tenascin-C isoform expression on tumour cell growth. (a) Growth of MCF-7, MDA-MB-231 and T-47 D cell lines
transfected with three different tenascin-C (TNC) constructs and a vector control. Bars represent the mean relative cell count compared with 0
hours, with each assay performed three times in triplicate; error bars shown. (b) Images of cells transfected with three different TNC constructs.
Images were taken using a 4× magnification in exactly the same position in each well. **P < 0.01, ***P < 0.001.
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Page 11 of 14tumours in young women are biologically distinct, how-
ever, being associated with poorer survival independent
of tumour grade and stage [58] and showing a higher
frequency of loss of heterozygosity compared with
grade-matched and stage-matched postmenopausal can-
cers [59]. The association of AD1 and AD2 expression
with younger age supports the hypothesis that these
tumours are biologically distinct.
Over recent years there has been increasing recogni-
tion of a subgroup of breast carcinomas characterised
by high levels of expression of genes and proteins nor-
mally associated with the myoepithelial or basal cell
population of the breast [33,34,36,60]. This basal tumour
subtype exhibits a poorer prognosis than other sub-
groups [60], occurs with high frequency in BRCA1-
mutated tumours [36] and occurs more frequently in
younger women [60]. To address whether the TNC-
AD1 (myoepithelial-associated) and TNC-AD2 isoforms
were associated with basal features, we compared TNC-
AD1 status with expression of putative basal markers
[33,34]. There was no association of TNC-AD1 expres-
sion with either the triple-negative or CK 5/6-positive
and/or CK14-positive subtypes, or with any of the other
putative basal markers. This may be due to relatively
small numbers of basal cases available for analysis, but a
larger study was precluded by the need for fresh tissue
for analysis.
Conclusions
The present study has shown a highly significant asso-
ciation between expression of TNC-AD1 and TNC-AD2
and carcinomas arising in young women (≤40 years),
and TNC-AD1 is sometimes incorporated into a novel
tumour-associated TNC isoform not detected in normal
tissues. The association of TNC-AD1 expression with
tumours arising in young women and also with high-
grade and ER-negative tumours make it a plausible tar-
get for development of novel therapies. Functional stu-
dies showed that the TNC-14/AD1/16 isoform can
significantly increase breast cancer cell invasion and
growth, to a greater extent than the previously described
tumour-associated TNC-9/14/16 isoform. This raises
interesting questions regarding the functional signifi-
cance of TNC isoforms containing the AD domains.
Additional material
Additional file 1: Western blot analysis of TNC expression in
transiently transfected MCF-7 cells. Figure demonstrating a single
species of TNC present in the conditioning media and whole-cell lysate.
TNC-S is seen as a band at approximately 200 kDa, with slightly larger
bands detected for TNC-B/D (exons 14/16) and TNC-B/AD1/D (exons 14/
AD1/16), with TNC-B/AD1/D detected at approximately 270 kDa.
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